128
Participants
Start Date
November 13, 2019
Primary Completion Date
October 15, 2021
Study Completion Date
October 26, 2021
Valbenazine
vesicular monoamine transporter 2 (VMAT2) inhibitor
Placebo
non-active dosage form
Neurocrine Clinical Site, Williamsville
Neurocrine Clinical Site, Rochester
Neurocrine Clinical Site, Pittsburgh
Neurocrine Clinical Site, Washington D.C.
Neurocrine Clinical Site, Charlottesville
Neurocrine Clinical Site, Durham
Neurocrine Clinical Site, Columbia
Neurocrine Clinical Site, Charleston
Neurocrine Clinical Site, Greenville
Neurocrine Clinical Site, Atlanta
Neurocrine Clinical Site, Gainesville
Neurocrine Clinical Site, Miami
Neurocrine Clinical Site, Birmingham
Neurocrine Clinical Site, Nashville
Neurocrine Clinical Site, Louisville
Neurocrine Clinical Site, Columbus
Neurocrine Clinical Site, Toledo
Neurocrine Clinical Site, Cleveland
Neurocrine Clinical Site, Indianapolis
Neurocrine Clinical Site, Ann Arbor
Neurocrine Clinical Site, West Bloomfield
Neurocrine Clinical Site, Iowa City
Neurocrine Clinical Site, Fargo
Neurocrine Clinical Site, Chicago
Neurocrine Clinical Site, Chicago
Neurocrine Clinical Site, Kansas City
Neurocrine Clinical Site, Wichita
Neurocrine Clinical Site, Omaha
Neurocrine Clinical Site, New Orleans
Neurocrine Clinical Site, Little Rock
Neurocrine Clinical Site, Houston
Neurocrine Clinical Site, Aurora
Neurocrine Clinical Site, Englewood
Neurocrine Clinical Site, Salt Lake City
Neurocrine Clinical Site, La Jolla
Neurocrine Clinical Site, Sacramento
Neurocrine Clinical Site, Seattle
Neurocrine Clinical Site, Spokane
Neurocrine Clinical Site, Boston
Neurocrine Clinical Site, Boston
Neurocrine Clinical Site, Charlestown
Neurocrine Clinical Site, Burlington
Neurocrine Clinical Site, Vancouver
Neurocrine Clinical Site, Ottawa
Neurocrine Clinical Site, Toronto
Neurocrine Clinical Site, Toronto
Lead Sponsor
Huntington Study Group
NETWORK
Neurocrine Biosciences
INDUSTRY